Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory.
中国最大CAP标准实验室中427例浸润性宫颈癌的既往高危型HPV检测及巴氏检测结果
Abstract
Cervical cancer and its precursor lesions are caused by a persistent high-risk human papillomavirus (hrHPV) infection. hrHPV testing has been reported to have higher sensitivity than Papanicolaou (Pap) testing for the detection of cervical precursor lesions. However, limited data are available for prior human papillomavirus (HPV) testing results for patients later diagnosed with invasive cervical cancer, especially in countries lacking a national cervical cancer screening program such as China. This study investigated prior hrHPV testing results for patients with invasive cervical cancer in China.
Cases with a histologic diagnosis of invasive cervical carcinoma were retrieved from Guangzhou KingMed Diagnostics (the largest independent pathology laboratory in China); prior hrHPV and Pap test results obtained within the year before the cancer diagnosis were recorded.
HPV testing was negative in 7.5% of 427 cases of invasive cervical carcinoma, including squamous cell carcinoma (5%) and adenocarcinoma (25%). In 155 cervical cancer cases with prior hrHPV and Pap testing, the negative rate for Pap testing was 1.9%, and the negative rate for HPV was 9.7%. Furthermore, when only cases of adenocarcinoma (n = 18) were examined, both the hrHPV-negative rate and the Pap-negative rate were higher at 33% and 5.6%, respectively.
These data demonstrate a considerable prior hrHPV-negative rate and a lower prior Pap-negative rate in patients with invasive cervical carcinoma (especially adenocarcinoma) from a population of women without access to an established screening program. Cancer (Cancer Cytopathol) 2015;123:428-34. © 2015 American Cancer Society.
Cases with a histologic diagnosis of invasive cervical carcinoma were retrieved from Guangzhou KingMed Diagnostics (the largest independent pathology laboratory in China); prior hrHPV and Pap test results obtained within the year before the cancer diagnosis were recorded.
HPV testing was negative in 7.5% of 427 cases of invasive cervical carcinoma, including squamous cell carcinoma (5%) and adenocarcinoma (25%). In 155 cervical cancer cases with prior hrHPV and Pap testing, the negative rate for Pap testing was 1.9%, and the negative rate for HPV was 9.7%. Furthermore, when only cases of adenocarcinoma (n = 18) were examined, both the hrHPV-negative rate and the Pap-negative rate were higher at 33% and 5.6%, respectively.
These data demonstrate a considerable prior hrHPV-negative rate and a lower prior Pap-negative rate in patients with invasive cervical carcinoma (especially adenocarcinoma) from a population of women without access to an established screening program. Cancer (Cancer Cytopathol) 2015;123:428-34. © 2015 American Cancer Society.
摘要
宫颈癌及其癌前病变是由持续存在的高危型人乳头瘤病毒（hrHPV）感染引起。据报道，hrHPV检测较巴氏（Pap）检测在发现宫颈癌前病变方面具有较高的敏感性。然而，具有早期人乳头瘤病毒（HPV）检测结果的患者而后诊断为浸润性宫颈癌的数据有限，特别是在像中国这样缺乏全国性宫颈癌筛查计划的国家。本研究调查了中国浸润性宫颈癌患者早期hrHPV检测结果。
收集广州金域诊断中心（中国最大独立性病理学实验室）组织学诊断为浸润性宫颈癌的病例，记录诊断宫颈癌之前1年的早期hrHPV检测及巴氏检测结果。
427例浸润性宫颈癌中，HPV检测阴性的为7.5%，包括鳞状细胞癌（5%）和腺癌（2.5%）。155例宫颈癌患者进行了早期hrHPV检测和巴氏检测，巴氏检测阴性率为1.9%，而HPV检测阴性率为9.7%。此外，当仅对腺癌病例（n=18）检测而言，hrHPV检测和巴氏检测的阴性率较高，分别为33%和5.6%。
这些数据显示，在未进行标准筛查的女性人群中，浸润性宫颈癌（特别是腺癌）患者具有相当高的早期hrHPV检测阴性率以及较低的巴氏检测阴性率。
我要评论
共0条评论